Alvotech, a global biotech company, has announced a new supply and commercialization agreement with Advanz Pharma for AVT10, their biosimilar candidate to Cimzia® (certolizumab pegol). This marks a significant step as it is the only biosimilar referencing Cimzia® currently under development worldwide. The reference product, Cimzia®, is widely used for treating chronic rheumatic diseases, particularly among women of childbearing age. The agreement aims to expand access to high-quality biologics for patients in Europe and is a continuation of the strategic partnership between Alvotech and Advanz Pharma. The companies plan to launch their first biosimilars in Europe in the fourth quarter of 2025. Cimzia® achieved worldwide sales of $2.3 billion in 2024.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。